Literature DB >> 23443971

Metabolic phenotypes in triple-negative breast cancer.

Sewha Kim1, Do Hee Kim, Woo-Hee Jung, Ja Seung Koo.   

Abstract

The aim of study was to investigate the metabolism of tumor and stromal cells necessary to determine differential tumor-stroma metabolic interactions according to the molecular subtypes of triple-negative breast cancer (TNBC). Tissues from 132 patients of TNBC were prepared for use as tissue microarrays (TMA). Expression of CK5/6, EGFR, claudin 3, claudin 4, claudin7, E-cadherin, AR, GGT1, STAT1, and interleukin-8 was evaluated by immunohistochemical staining using TMA to classify molecular subtypes of TNBC. In addition, immunohistochemical staining for Glut1, CAIX, BNIP3, MCT4, Beclin-1, LC3A, LC3B, and p62 was performed. According to glycolytic status determined by the immunohistochemical expression of Glut-1 and CAIX in tumor and stroma, the metabolic phenotypes of the TNBCs were defined as follows: Warburg type (tumor: glycolysis, stroma: non-glycolysis), reverse Warburg type (tumor: non-glycolysis, stroma: glycolysis), mixed metabolic type (tumor: glycolysis, stroma: glycolysis), and metabolic null type (tumor: non-glycolysis, stroma: non-glycolysis). TNBCs were classified as follows: 79 Warburg type (59.8 %), 7 reverse Warburg type (5.3 %), 24 mixed metabolic type (18.2 %), and 22 metabolic null type (16.7 %). There was no statistical significance between the metabolic phenotypes and molecular subtypes (P=0.706). Reverse Warburg type showed the most dysfunctional mitochondrial status for stromal cells, while Warburg type showed the most functional mitochondrial status (P=0.036). Regarding stromal autophagy status, reverse Warburg type showed the most activated status, while all of the Warburg and metabolic null types showed a non-activated status (P<0.001). In conclusion, Warburg type was the most common metabolic phenotype in TNBC, while reverse Warburg type was the most unusual. Metabolic phenotypes did not differ among the molecular subtypes of TNBCs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23443971     DOI: 10.1007/s13277-013-0707-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  29 in total

1.  Molecular stratification of triple-negative breast cancers.

Authors:  Charles M Perou
Journal:  Oncologist       Date:  2011

2.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

Review 3.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

4.  Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers.

Authors:  Agnieszka K Witkiewicz; Diana Whitaker-Menezes; Abhijit Dasgupta; Nancy J Philp; Zhao Lin; Ricardo Gandara; Sharon Sneddon; Ubaldo E Martinez-Outschoorn; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2012-03-15       Impact factor: 4.534

Review 5.  Glucose metabolism and cancer.

Authors:  Reuben J Shaw
Journal:  Curr Opin Cell Biol       Date:  2006-10-12       Impact factor: 8.382

6.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

7.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

8.  Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma.

Authors:  Céline Pinheiro; André Albergaria; Joana Paredes; Bárbara Sousa; Rozany Dufloth; Daniella Vieira; Fernando Schmitt; Fátima Baltazar
Journal:  Histopathology       Date:  2010-06       Impact factor: 5.087

9.  Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry.

Authors:  Junjeong Choi; Woo-Hee Jung; Ja Seung Koo
Journal:  Pathobiology       Date:  2012-07-24       Impact factor: 4.342

10.  Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer.

Authors:  Christopher J Ricketts; Brian Shuch; Cathy D Vocke; Adam R Metwalli; Gennady Bratslavsky; Lindsay Middelton; Youfeng Yang; Ming-Hui Wei; Stephen E Pautler; James Peterson; Catherine A Stolle; Berton Zbar; Maria J Merino; Laura S Schmidt; Peter A Pinto; Ramaprasad Srinivasan; Karel Pacak; W Marston Linehan
Journal:  J Urol       Date:  2012-10-18       Impact factor: 7.450

View more
  30 in total

1.  Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer.

Authors:  Hye Ryoung Koo; Jeong Seon Park; Keon Wook Kang; Wonshik Han; In Ae Park; Woo Kyung Moon
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

Review 2.  Breast cancer: insights in disease and influence of drug methotrexate.

Authors:  Vítor Yang; Maria João Gouveia; Joana Santos; Beate Koksch; Irina Amorim; Fátima Gärtner; Nuno Vale
Journal:  RSC Med Chem       Date:  2020-05-28

3.  Targeting metabolic plasticity in breast cancer cells via mitochondrial complex I modulation.

Authors:  Qijin Xu; Eva Biener-Ramanujan; Wei Yang; V Krishnan Ramanujan
Journal:  Breast Cancer Res Treat       Date:  2015-02-13       Impact factor: 4.872

4.  ¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.

Authors:  Flavio Crippa; Roberto Agresti; Marco Sandri; Gabriella Mariani; Barbara Padovano; Alessandra Alessi; Giulia Bianchi; Emilio Bombardieri; Ilaria Maugeri; Mario Rampa; Maria Luisa Carcangiu; Giovanna Trecate; Claudio Pascali; Anna Bogni; Gabriele Martelli; Filippo de Braud
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-12       Impact factor: 9.236

5.  A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming.

Authors:  Hassan Yousefi; Maninder Khosla; Lothar Lauterboeck; Samuel C Okpechi; David Worthylake; Jone Garai; Jovanny Zabaleta; Jessie Guidry; Mohammad Amin Zarandi; Dorota Wyczechowska; Janarthanan Jayawickramarajah; Qinglin Yang; Joseph Kissil; Suresh K Alahari
Journal:  Oncogene       Date:  2022-10-15       Impact factor: 8.756

6.  Mitophagy defects arising from BNip3 loss promote mammary tumor progression to metastasis.

Authors:  Aparajita H Chourasia; Kristin Tracy; Casey Frankenberger; Michelle L Boland; Marina N Sharifi; Lauren E Drake; Joseph R Sachleben; John M Asara; Jason W Locasale; Gregory S Karczmar; Kay F Macleod
Journal:  EMBO Rep       Date:  2015-07-31       Impact factor: 8.807

7.  Effect of GLUT1 Inhibition and Autophagy Modulation on the Growth and Migration of Laryngeal Carcinoma Stem Cells Under Hypoxic and Low-Glucose Conditions.

Authors:  Xiao-Hong Chen; Jia Liu; Jiang-Tao Zhong; Shui-Hong Zhou; Jun Fan
Journal:  Onco Targets Ther       Date:  2021-05-11       Impact factor: 4.147

8.  Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer.

Authors:  Malathi Banda; Cecilia L Speyer; Sara N Semma; Kingsley O Osuala; Nicole Kounalakis; Keila E Torres Torres; Nicola J Barnard; Hyunjin J Kim; Bonnie F Sloane; Fred R Miller; James S Goydos; David H Gorski
Journal:  PLoS One       Date:  2014-01-03       Impact factor: 3.240

9.  Cancer stem cell theory and the warburg effect, two sides of the same coin?

Authors:  Nicola Pacini; Fabio Borziani
Journal:  Int J Mol Sci       Date:  2014-05-19       Impact factor: 5.923

10.  A joint analysis of metabolomics and genetics of breast cancer.

Authors:  Xiaohu Tang; Chao-Chieh Lin; Ivan Spasojevic; Edwin S Iversen; Jen-Tsan Chi; Jeffrey R Marks
Journal:  Breast Cancer Res       Date:  2014-08-05       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.